Specifically, in PDAC xenograft models, Tasaki et al. found that the targeting of TUG1 by ASO combined with their new cancer-specific drug delivery system could effectively reduce drug resistance and the systemic adverse effects of chemotherapy [98]. Here, TUG1 is linked to cancer.